Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor
Dopamine agonists (DAs, especially cabergoline) are recommended as first-line treatment
in patients with prolactin-secreting pituitary adenomas, to reduce hormone secretion and …
in patients with prolactin-secreting pituitary adenomas, to reduce hormone secretion and …
Temozolomide nonresponsiveness in aggressive prolactinomas and carcinomas: management and outcomes
Context Temozolomide (TMZ) is endorsed as the treatment of choice in aggressive or
malignant pituitary adenomas. Objective Herein we describe a case of an aggressive …
malignant pituitary adenomas. Objective Herein we describe a case of an aggressive …
Temozolomide in the management of dopamine agonist–resistant prolactinomas
BC Whitelaw, D Dworakowska… - Clinical …, 2012 - Wiley Online Library
Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response
RE Strowd, R Salvatori… - Journal of Oncology …, 2016 - journals.sagepub.com
Background Temozolomide is an oral alkylating agent with schedule-dependent antitumor
activity against high-grade malignancies including high-grade glioma. Increasingly, reports …
activity against high-grade malignancies including high-grade glioma. Increasingly, reports …
[PDF][PDF] Treatment of aggressive prolactin-secreting pituitary adenomas with adjuvant temozolomide chemotherapy: a review
Most prolactin-secreting pituitary adenomas demonstrate slow growth and are effectively
managed with medical/surgical therapy. Rarely, these tumors can behave aggressively with …
managed with medical/surgical therapy. Rarely, these tumors can behave aggressively with …
[HTML][HTML] Effective long-term temozolomide rechallenge in a macroprolactinoma
B Zampetti, G Simonetti, R Attanasio… - … & Metabolism Case …, 2018 - edm.bioscientifica.com
We describe the 20-year course of a 63-year-old male with a macroprolactinoma that
acquired resistance to treatment and aggressive behavior after a 4-year successful …
acquired resistance to treatment and aggressive behavior after a 4-year successful …
Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review
MH Almalki, NN Aljoaib, MJ Alotaibi, BS Aldabas… - Hormones, 2017 - Springer
Abstract Pituitary tumors represent 10–15% of all intracranial tumors; of these, prolactinomas
account for 40–50% of cases. Prolactinomas usually respond well to dopamine agonists …
account for 40–50% of cases. Prolactinomas usually respond well to dopamine agonists …
Early recognition and initiation of temozolomide chemotherapy for refractory, invasive pituitary macroprolactinoma with long-term sustained remission
G Barkhoudarian, SK Palejwala, R Ogunbameru… - World Neurosurgery, 2018 - Elsevier
Objective Invasive, medically refractory, and multiply recurrent pituitary adenomas pose a
rare, but nevertheless significant, challenge for conventional management modalities …
rare, but nevertheless significant, challenge for conventional management modalities …
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
LM Neff, M Weil, A Cole, TR Hedges, W Shucart… - Pituitary, 2007 - Springer
Prolactinomas are common tumors of the anterior pituitary gland. While conventional
therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are …
therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are …